TP53 and prostate carcinoma: Similarly, in RTOG 86-10, a phase III trial of Zoladex and flutamide in locally advanced carcinoma of the prostate treated with definitive radiotherapy, patients were assessed for the prognostic significance of abnormal p53 expression.